Anti-ADAM10 antibody (8C7) for cancer therapy (Oncology - tumour specific monoclonal antibody)
- Detailed Technology Description
- Anti-ADAM10 antibody (8C7) for cancer therapy. An antibody that binds a proteolytically active form of an ADAM protease. This invention can be utilised in the diagnosis and/or treatment of cancers.
- *Abstract
-
Novel mAbs that bind a unique epitope on a cancer-associated form of the ADAM10 metalloprotease. Inhibiting ADAM10 blocks activation of receptors linked to the 'stem cell niche' and depletes cancer stem cells resistant to chemotherapeutic treatments in vivo. The lead mAb is potentially useful as 'cancer specific' single agent, drug conjugate and/or combination therapy.
* Novel mAbs that specifically bind and inhibit a unique cancer-specific form of the ADAM10 protease
* In vivo PoC data shows single agent and combination efficacy
* Potential use as naked and/or functionalised (ADC) therapeutic
* Targets 'stem cell niche' to sensitise chemoresistant tumours
- Country/Region
- USA
For more information, please click Here
